CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-05-12 | HEGGIE THERESA Director | Grant or award · Automatic Stock Option Grant | +40,000 | 40,000 | ||
| 2020-05-12 | ASELAGE STEVE Director | Grant or award · Automatic Stock Option Grant | +40,000 | 40,000 | ||
| 2020-05-12 | ABERCROMBIE GEORGE B Director | Grant or award · Automatic Stock Option Grant | +40,000 | 40,000 | ||
| 2020-04-30 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2020-03-01 | ASELAGE STEVE Director | Grant or award | +1,666 | $3.00 | $5K | 25,092 |
| 2020-03-01 | HEGGIE THERESA Director | Grant or award | +1,666 | $3.00 | $5K | 10,092 |
| 2020-03-01 | Hutson Nancy J Director | Grant or award | +3,333 | $3.00 | $10K | 59,887 |
| 2020-03-01 | INGRAM ROBERT ALEXANDER Director | Grant or award | +6,250 | $3.00 | $19K | 60,916 |
| 2020-02-27 | LEVIN ALAN G Director | Grant or award · Non-Qualified Stock Option | +15,000 | 15,000 | ||
| 2020-02-21 | Jones Michael L Exec. Director, Finance - PAO | Grant or award · Emp. Stock Option (Right to Buy) | +2,800 | 2,800 | ||
| 2020-02-21 | Barnes Alane P Senior VP, Chief Legal Officer | Grant or award · Emp. Stock Option (Right to Buy) | +12,400 | 12,400 | ||
| 2020-02-21 | Babu Yarlagadda S Senior VP - Drug Discovery | Grant or award · Emp. Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2020-02-21 | Sheridan William P Senior VP - CMO | Grant or award · Emp. Stock Option (Right to Buy) | +22,600 | 22,600 | ||
| 2020-02-21 | STAAB THOMAS R II Senior Vice President and CFO | Grant or award · Emp. Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2020-02-21 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +27,140 | 27,140 | ||
| 2020-02-14 | Jones Michael L Exec. Director, Finance - PAO | Grant or award · Emp. Stock Option (Right to Buy) | +4,900 | 4,900 | ||
| 2020-02-14 | Barnes Alane P Senior VP, Chief Legal Officer | Grant or award · Emp. Stock Option (Right to Buy) | +21,700 | 21,700 | ||
| 2020-02-14 | Babu Yarlagadda S Senior VP - Drug Discovery | Grant or award · Emp. Stock Option (Right to Buy) | +31,500 | 31,500 | ||
| 2020-02-14 | Sheridan William P Senior VP - CMO | Grant or award · Emp. Stock Option (Right to Buy) | +39,550 | 39,550 | ||
| 2020-02-14 | STAAB THOMAS R II Senior Vice President and CFO | Grant or award · Emp. Stock Option (Right to Buy) | +31,500 | 31,500 |
Page 26 of 27 · 522 trades